Ken Kato - Researcher Profile | RDL Research Database

Publications

4 shown

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun , Lin Shen , Manish A. Shah +22 more

Merck Sharp & Dohme.

2021 The Lancet 1394 citations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

James Lynam , Niall C. Tebbutt , Mark Wong +97 more

2018 The Lancet 1262 citations

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato , Byoung Chul Cho , Masanobu Takahashi +15 more

2019 The Lancet Oncology 1165 citations

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima , Manish A. Shah , Kei Muro +24 more

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...

2020 Journal of Clinical Oncology 1110 citations

Frequent Co-Authors

Researcher Info

h-index: 4
Publications: 4
Citations: 4,931
Institution: Tokyo National Hospital

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-1733-5072

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.